Transcranial electromagnetic treatment
AssigneeNeuroEM Therapeutics, Inc.
InventorsGary W. Arendash, Robert Baranowski
Life of this patent
Estimating the term…
Abstract
In one example in accordance with the present disclosure a method is described. According to the method, an emitter of a transcranial electromagnetic treatment (TEMT) system is positioned at a location relative to a head of a patient such that the emitter emits an electromagnetic frequency signal toward the head of the patient. The emitter is activated to apply TEMT to the patient to treat amyloid oligomers. In some examples, the TEMT has a frequency between 1 MHz and 430 THz.
Claims27
A method, comprising:
- positioning at least one emitter of a transcranial electromagnetic treatment (TEMT) system at a location relative to a head of a patient such that the emitter emits an electromagnetic frequency signal toward the head of the patient;
- and
- activating the emitter to apply TEMT to the patient to disaggregate amyloid oligomers.
A transcranial electromagnetic treatment (TEMT) system, comprising:
- an emitter array comprising a plurality of emitters;
- and
- a controller to control emission of radiation from each of the emitters by:
- directing a first emitter to broadcast a first signal toward the brain of the patient to disaggregate amyloid oligomers;
- and
- directing a second emitter to broadcast a second signal toward the brain of the patient to disaggregate amyloid oligomers.
A method, comprising:
- positioning an emitter of a transcranial electromagnetic treatment (TEMT) system at a first location relative to a head of a patient;
- activating the emitter to apply transcranial electromagnetic treatment (TEMT) with the emitter at the first location to disaggregate at least one of A-beta (Aβ), tau, p-tau, and alpha-synuclein oligomers;
- repositioning the emitter to a second location relative to the head of the patient;
- and
- activating the emitter to apply TEMT with the directional emitter at the second location to disaggregate at least one of Aβ, tau, p-tau, and alpha-synuclein oligomers.
A transcranial electromagnetic treatment (TEMT) system, comprising:
- a subcutaneous implant comprising:
- an emitter to emit a signal with a frequency between 1 megahertz (MHz) and 430 terahertz (THz), the signal directed toward a brain of a patient;
- and
- a controller to control emission of radiation from each of the emitter;
- and
- a power source to provide power to the subcutaneous implant.
Dependencies are inferred from the claim text.